25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Africa is still the next big market for multinationals, even in the face of global economic uncertai...
Read More >
On January 9, 2020, the National Institute of Statistics and Geography (INEGI by its acronym in Span...
Read More >
Don’t let hindsight be 2020. While others are enjoying the holidays and a well-deserved break, Neva...
Read More >
A new Virginia statute limits employers’ use of nondisclosure and confidentiality agreements with r...
Read More >
Retailer Permitted Disability Harassment at West Virginia Store, Then Retaliated Against Employee Fo...
Read More >
On December 18, 2019, the National Labor Relations Board (NLRB) published final rules that will take...
Read More >